Sanofi-Aventis Poland

Last updated: 01.06.2015

Address: ul. Bonifraterska 17
00-203 Warszawa

Tel: 022 280 00 00


Company description

Sanofi-aventis is a global healthcare leader

Focused on patients’ needs, sanofi-aventis offers a range of essential healthcare assets, including a broad-based product portfolio and a presence worldwide.

At a glance

2010 sales: €30.384 billion
A broad portfolio of pharmaceutical products: prescription medicines, generics, consumer health care and animal health
World leader in human vaccines
A broad and balanced presence on both traditional and emerging markets
Around 102,000 employees in 100 countries
Group strategy

Our ambition is to become a diversified global healthcare leader. Our strategy is built around three priorities to reach its goals and ensure sustainable growth:

Innovation in Research and Development
Adaptation of Group structures
External growth opportunities

Products and services

Prescription medicines

In 2010, pharmaceutical sales were of €26.676 million driven by the Group’s major prescription products in particular in the field of diabetes, oncology and thrombosis.

Among these, Lantus® confirms its position as the leading brand of insulin on the world market with sales of €3,510 million in 2010, boosted by the success of the SoloSTAR® pen injector. In the United-States, these figures include an accrual related to U.S. health care reform and were impacted by a reduction in inventory.

In January 2011, the FDA updated its ongoing safety review of Lantus®. In addition to the analysis of the four studies published in Diabetologia, the FDA also reviewed results from a five-year diabetic retinopathy clinical trial in patients with Type 2 Diabetes. At this time and based on these data, FDA has not concluded that Lantus increases the risk of cancer.

The range of products in the field of diabetes also includes Apidra® and Amaryl®.

The Group’s other major prescription drugs are Lovenox®, Taxotere®, Plavix®, Aprovel®, Eloxatin®, and Multaq®.

Jevtana®, a new anti-cancer agent, was approved on June 17, 2010 by the FDA following a priority review and launched in the U.S. on July 19, 2010 for patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-based therapy.

Human Vaccines

Sanofi Pasteur, the vaccines division of sanofi-aventis, is a global leader with the world’s broadest range of human vaccines.

Among the major vaccines there are the Polio/Pertussis/Hib vaccines such as Pentacel® and Pentaxim®, along with influenza vaccines (Vaxigrip® et Fluzone®) against seasonal flu, meningitis and pneumonia vaccines (incuding. Menactra®), adult booster vaccines (including Adacel ®) and travel and other endemics vaccines.

Year-to-date consolidated net sales for the Human Vaccines business were of €3,808 million.


In 2010, sales of the generics business grew to €1,534 million, due to acquisitions completed in 2009 and solid organic growth especially in Eastern Europe and Brazil as well as in the U.S where an authorized generic of Ambien®CR was launched during the period.

Consumer Healthcare

Sanofi-aventis is a mayor player in the global market of Consumer Healthcare. In 2010, the sales of this activity reached €2,217 million reflecting the contribution from the acquisitions of Chattem, Nepentes and Oenobiol.

The eight international brands² are: Doliprane®, Essentiale®, No-Spa®, Maalox®, Enterogermina®, Magne B6®, Dorflex®, and Lactacyd®.

Animal Health

Merial, a wholly-owned sanofi-aventis subsidiary is a leading producer of animal health products with Frontline® and Heartgard®. Merial posted net sales of 2,635 million US dollars in 2010.